1061 — Essex Bio-Technology Income Statement
0.000.00%
Last trade - 00:00- HK$2.05bn
- HK$1.61bn
- HK$1.81bn
Annual income statement for Essex Bio-Technology, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | HKAS | HKAS | HKAS | HKAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,638 | 1,318 | 1,737 | 1,670 | 1,814 |
| Cost of Revenue | |||||
| Gross Profit | 1,396 | 1,189 | 1,562 | 1,499 | 1,618 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,234 | 1,046 | 1,378 | 1,285 | 1,391 |
| Operating Profit | 404 | 272 | 359 | 384 | 423 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 394 | 260 | 346 | 376 | 415 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 346 | 225 | 275 | 307 | 318 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 346 | 225 | 275 | 307 | 318 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 350 | 229 | 279 | 310 | 318 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.582 | 0.439 | 0.479 | 0.507 | 0.561 |
| Dividends per Share |